Session Description

Secondary antibody deficiency (SAD) is common in patients with haematological malignancies, such as chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or after advanced therapies like B-cell targeting monoclonal antibodies or CAR T-cell therapy. During the session, our experts will discuss the latest advances on how to reduce infection burdens in these high-risk patients, for whom these infections remain a major cause of morbidity and mortality.